HTHQ 1-O-hexyl-2,3,5-trimethylhydroquinone; HX-1171; BTT-105|cas:148081-72-5|西域试剂

HTHQ 1-O-hexyl-2,3,5-trimethylhydroquinone; HX-1171; BTT-105,99.89%

产品编号：Bellancom-100768| CAS NO：148081-72-5| 分子式：C₁₅H₂₄O₂| 分子量：236.35

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100768	￥650.00	杭州北京（现货）
Bellancom-100768	￥950.00	杭州北京（现货）
Bellancom-100768	￥1500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

HTHQ 1-O-hexyl-2,3,5-trimethylhydroquinone; HX-1171; BTT-105

产品介绍

HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone) 是一种强力的亲脂性酚类抗氧化剂。HTHQ 通过与活性氧 (ROS) 直接反应并清除 ROS 以形成更稳定的自由基而具有很强的抗氧化活性。

生物活性

HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone) is a potent lipophilic phenolic antioxidant. HTHQ has considerable anti-oxidative activity by directly reacting with reactive oxygen species (ROS) and scavenging ROS to form more stable free radicals.

体外研究

HTHQ (0-100 μM; 24 hours; PC12 cells) treatment increases cell viabilities in a dose-dependent manner.
HTHQ (10 μM; 0.6-24 hours; PC12 cells) inhibits 3,4-L-Dihydroxyphenylalanine (L-DOPA) -induced phosphorylation of sustaines extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). HTHQ also normalizes L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression, promoting cell survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	PC12 cells
Concentration:	0 μM, 1 μM, 10 μM, and 100 μM
Incubation Time:	24 hours
Result:	Reduced cell viability at 24 hours caused by both 100 and 200 µM L-DOPA was significantly attenuated.

Western Blot Analysis

Cell Line:	PC12 cells
Concentration:	10 μM
Incubation Time:	0.6-24 hours
Result:	Inhibited L-DOPA-induced phosphorylation of sustained extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). And also normalized L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression.

体内研究
(In Vivo)

HTHQ (50-200 mg/kg; oral administration; for 4 weeks; specific pathogen-free male Sprague Dawley rats) treatment significantly improves liver weight and serum chemistry level. HTHQ reduces hydroxyproline and malondialdehyde level in the liver. HTHQ treatment also reduces fibrotic septa. HTHQ administration shows reduced mRNA level of PDGF (Plateletderived growth factor) , α-SMA (α-smooth muscle actin) and TGF-β (transforming growth factor-β) than DMN-induced hepetic fibrosis animals in the liver tissue.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	48 specific pathogen-free male Sprague Dawley (SD) rats (6-week-old ) with dimethylnitrosamine (DMN)
Dosage:	50 mg/kg, 100 mg/kg, 200 mg/kg
Administration:	Oral administration; for 4 weeks
Result:	Improved against DMN-induced liver fibrosis in male SD rats.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	48 specific pathogen-free male Sprague Dawley (SD) rats (6-week-old ) with dimethylnitrosamine (DMN)
Dosage:	50 mg/kg, 100 mg/kg, 200 mg/kg
Administration:	Oral administration; for 4 weeks
Result:	Improved against DMN-induced liver fibrosis in male SD rats.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	48 specific pathogen-free male Sprague Dawley (SD) rats (6-week-old ) with dimethylnitrosamine (DMN)
Dosage:	50 mg/kg, 100 mg/kg, 200 mg/kg
Administration:	Oral administration; for 4 weeks
Result:	Improved against DMN-induced liver fibrosis in male SD rats.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (423.10 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.2310 mL	21.1551 mL	42.3101 mL
5 mM	0.8462 mL	4.2310 mL	8.4620 mL
10 mM	0.4231 mL	2.1155 mL	4.2310 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 25 mg/mL (105.78 mM); Suspended solution; Need ultrasonic

此方案可获得 25 mg/mL (105.78 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 250.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.58 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.58 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。